China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development, reportedly raised upwards of RMB 100 million (USD 14.3 million) in a Pre-Series B financing round. Dachen Capital led the round, which included contributions from Huaxi Investment, FangSheng Capital, ZGC Co-Innovation Fund, and Tao Capital, alongside existing investors Gaorong Capital and Tsingyuan Ventures. Proceeds will be used to advance clinical programs and expand the pre-clinical pipeline.
Pipeline and Programs
4B Technologies boasts a pipeline consisting of nine novel programs, including amyotrophic lateral sclerosis therapy FB-1071 and acute optic nerve injury drug FB1001, both at clinical stages. In addition, its FB1003 and FB1008, for the treatment of chronic pain and Alzheimer’s disease respectively, are in pre-clinical stages.Fineline Info & Tech
